Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24637164 | 0.87 | SIGMAR1 (0.36) | EGFR | |
| SCHEMBL19912771 | 0.86 | PKM (0.36) | EGFRLMNAALDH1A1SMN1; SMN2JAK2 | |
| SCHEMBL19669740 | 0.86 | LMNA (0.38) | EGFRLMNAALDH1A1SMN1; SMN2JAK2 | |
| SCHEMBL19912779 | 0.85 | SMN1; SMN2 (0.45) | EGFRLMNAALDH1A1SMN1; SMN2JAK2 | |
| SCHEMBL19442308 | 0.84 | SMN1; SMN2 (0.47) | EGFRLMNAALDH1A1SMN1; SMN2JAK2 | |
| SCHEMBL19669738 | 0.83 | SMN1; SMN2 (0.38) | EGFRLMNAALDH1A1SMN1; SMN2JAK2 | |
| SCHEMBL15600836 | 0.82 | SIGMAR1 (0.41) | EGFRLMNAALDH1A1SMN1; SMN2JAK2 | |
| SCHEMBL15600841 | 0.81 | SMN1; SMN2 (0.53) | EGFRALDH1A1SMN1; SMN2 | |
| SCHEMBL19669739 | 0.81 | ALDH1A1 (0.35) | EGFRLMNAALDH1A1 | |
| SCHEMBL15601163 | 0.80 | KMT2A (0.36) | EGFRLMNAALDH1A1SMN1; SMN2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885LMNA 4404/4885ALDH1A1 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.